These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Controversies with Kalydeco: Newspaper coverage in Canada and the United States of the cystic fibrosis "wonder drug". Rachul C; Toews M; Caulfield T J Cyst Fibros; 2016 Sep; 15(5):624-9. PubMed ID: 27150823 [TBL] [Abstract][Full Text] [Related]
30. Affordable HIV and sickle cell disease gene therapies. Mullard A Nat Rev Drug Discov; 2019 Nov; 18(12):895. PubMed ID: 31780850 [No Abstract] [Full Text] [Related]
31. A cancer drug shows promise, at a price that many can't pay. Berenson A N Y Times Web; 2006 Feb; ():A1, C2. PubMed ID: 16506302 [No Abstract] [Full Text] [Related]
33. It's time for gene therapy to get disruptive! Wilson JM Hum Gene Ther; 2012 Jan; 23(1):1-3. PubMed ID: 22247960 [No Abstract] [Full Text] [Related]
34. Dismantling cost and infrastructure barriers to equitable access to gene therapies for sickle cell disease. Sharma A; John TD Lancet Haematol; 2024 Aug; 11(8):e556-e559. PubMed ID: 38964356 [No Abstract] [Full Text] [Related]
35. Must Sky-High Prices 'Come on Down' Before the Price Is Right? Kirkner RM Manag Care; 2018 Jul; 27(7):16-19. PubMed ID: 29989894 [TBL] [Abstract][Full Text] [Related]
36. Market watch : Pharma industry strategic performance: 2007-2012E. Goodman M Nat Rev Drug Discov; 2008 Dec; 7(12):967. PubMed ID: 19043444 [No Abstract] [Full Text] [Related]
39. When the price is right. Nat Biotechnol; 2006 May; 24(5):473. PubMed ID: 16680108 [No Abstract] [Full Text] [Related]
40. Sweat chloride is not a useful marker of clinical response to Ivacaftor. Barry PJ; Jones AM; Webb AK; Horsley AR Thorax; 2014 Jun; 69(6):586-7. PubMed ID: 24258833 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]